Jasper Therapeutics, Inc. to acquire Kira Pharmaceuticals

Jasper Therapeutics, Inc. has agreed to acquire Kira Pharmaceuticals in a strategic acquisition within the healthcare sector. The transaction, announced on 16 July 2026, involves the US-based buyer purchasing the Kentucky-headquartered target. Consideration for the deal is structured entirely through shares. The specific financial value of the transaction has not been disclosed to the public, and no currency was reported alongside the equity-based payment terms. This arrangement represents a significant consolidation of assets within the biotechnology and pharmaceutical landscape, bringing together the operational capabilities of both entities under a single corporate umbrella. The deal highlights the ongoing trend of larger therapeutic firms expanding their pipeline and market presence through targeted acquisitions of specialised research and development companies.

The transaction is now reported as completed. This final status indicates that all necessary regulatory approvals and internal corporate governance steps have been successfully concluded. The integration of Kira Pharmaceuticals into Jasper Therapeutics marks the end of the independent existence of the target company. Stakeholders can expect the combined entity to proceed with unified strategic initiatives and operational synergies. The completion of this share-based acquisition solidifies the new corporate structure and allows for the immediate reallocation of resources across the expanded organisation. This milestone concludes the public phase of the deal process.